Relationship of psychotic symptoms to haloperidol‐stimulated prolactin release

Acta Psychiatrica Scandinavica - Tập 82 Số 4 - Trang 271-274 - 1990
Jayashri Kulkarni1, Nicholas A Keks1, Geoffrey W. Stuart1, Belinda S. Mackie1, I. Harry Minas1, Bruce Singh1, David Copolov1
1National Health and Medical Research Council Schizophrenia Research Unit, Mental Health Research Institute of Victoria and Monash University Department of Psychological Medicine, Royal Park Hospital, Parkville, Victoria, Australia

Tóm tắt

ABSTRACTProlactin (PRL) response to a single dose of intravenous haloperidol (0.5 mg) was measured as a marker of tuberoinfundibular dopamine (TIDA) activity in 24 neuroleptic‐free, male, psychotic patients. The PRL responses were then correlated with psychotic symptoms measured with Andreasen's Scales for the Assessment of Positive and Negative Symptoms (SAPS, SANS). Correlation analyses revealed a significant inverse relationship between PRL response and the severity of delusional symptoms. There was no significant correlation between the symptoms of hallucinations, formal thought disorder, or global negative symptoms and PRL response to haloperidol, nor were there any significant correlations between basal PRL and symptom severity. These results suggest that among the positive and negative symptoms associated with psychoses, only delusions may be associated with TIDA overactivity.

Từ khóa


Tài liệu tham khảo

10.1001/archpsyc.1982.04290070025006

10.1016/0306-4530(80)90015-3

10.1007/BF00426804

10.1016/0306-4530(81)90047-0

10.1176/ajp.144.10.1335

10.1093/schbul/2.1.19

Seeman P., 1980, Brain dopamine receptors, Pharmacol Rev, 32, 229

Andreasen NC., 1983, The scale for the assessment of positive symptoms (SAPS)

Andreasen NC., 1984, The scale for the assessment of negative symptoms (SANS)

American Psychiatric Association, 1980, Diagnostic and statistical manual of mental disorders

10.2466/pr0.1962.10.3.799

World Health Organization, 1985, Reproductive physiology method manual

Dixon WJ, 1983, BMDP statistical software

10.1093/schbul/11.3.471

10.1136/bmj.280.6207.66

10.1001/archpsyc.1983.01790220030005

Cleghorn J., 1983, Growth hormone responses to graded doses of apomorphine HCL in schizophrenia, Biol Psychiatry, 18, 875

10.1001/archpsyc.1986.01800120048010

10.1016/0165-1781(86)90111-3

10.1001/archpsyc.1974.01760160102021

Asgrist B, 1970, The phenomenology of experimentally‐induced amphetamine psychosis: preliminary observations, Am J Psychiatry, 126, 95

Henn FA., 1980, Perspectives in schizophrenia research, 209

10.1136/bmj.2.4880.122

10.1111/j.1749-6632.1957.tb40764.x

Hil TM, 1969, The use of LSD and ditran in the treatment of therapy resistant schizophrenics (symptom provocation approach), Dis Nerv Syst, 30, 90

10.1136/jnnp.37.8.941

10.1111/j.2042-7158.1974.tb09362.x

10.1192/bjp.137.4.379

Crow TJ, 1982, Brain peptides and hormones, 43

Thông tin
Thông tin xuất bản

Acta Psychiatrica Scandinavica

Tập 82 Số 4

271-274

Thông tin tác giả